Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human fibrinogen Aα610
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant human fibrinogen Aα610 (rhFbgAα610) is a recombinant wild-type variant of human fibrinogen developed by the Leids Universitair Medisch Centrum (LUMC) in Leiden, Netherlands. It is being investigated for the treatment and prevention of coagulation disorders and coagulopathy, particularly perioperative bleeding in patients undergoing cardiac surgery such as coronary artery bypass graft (CABG) surgery. The drug acts by supplementing fibrinogen levels, thereby targeting the coagulation cascade to promote clot formation and restore hemostasis. In the ex vivo clinical trial context (the FIBRINOGEN study), rhFbgAα610 is compared with another recombinant variant (Aα847) and the plasma-derived fibrinogen concentrate Haemocomplettan to evaluate its effects on blood coagulation and fibrinolysis using rotational thromboelastometry (ROTEM).
- Other names
- recombinant human fibrinogen Aα610rhFGN variant Aα610recombinant human fibrinogen variant Aα610wild-type recombinant human fibrinogen
02
Targets
GPVI (Platelet glycoprotein VI)GPIIb/IIIa (Integrin alpha-IIb/beta-3)
Beyond the preview
Go deeper on recombinant human fibrinogen Aα610.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human fibrinogen Aα610.